Association of serum monomeric periostin level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia

被引:6
|
作者
Shimizu, Hiroshige [1 ]
Sakamoto, Susumu [1 ]
Okamoto, Masaki [2 ]
Isshiki, Takuma [1 ]
Ono, Junya [3 ]
Shimizu, Shigeki [4 ]
Hoshino, Tomoaki [2 ]
Izuhara, Kenji [5 ]
Homma, Sakae [1 ,6 ]
机构
[1] Toho Univ, Dept Resp Med, Omori Med Ctr, Tokyo, Japan
[2] Kurume Univ, Dept Internal Med, Sch Med, Div Respirol Neurol & Rheumatol, Fukuoka, Japan
[3] Shino Test Corp, Sagamihara, Kanagawa, Japan
[4] Kindai Univ, Dept Pathol, Fac Med, Osaka, Japan
[5] Saga Med Sch, Dept Biomol Sci, Div Med Biochem, Saga, Japan
[6] Toho Univ, Sch Med, Dept Adv & Integrated Interstitial Lung Dis Res, Tokyo, Japan
关键词
Acute exacerbation; fibrosing interstitial pneumonia; monomeric periostin; RISK-FACTORS; PROTEIN; FEATURES; DISEASE;
D O I
10.21037/atm-21-414
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The associations of serum monomeric periostin (M-PN) level and serial change in M-PN with acute exacerbation of chronic fibrosing interstitial pneumonia (AE-FIP) are unclear. Methods: We prospectively measured serum M-PN level from onset of AE to day 14 in 37 patients with AE-FIP and evaluated its association with outcome. To determine localization of periostin expression, immunohistochemical staining of pathological lung tissue from autopsy cases of AE-IPF was evaluated. Results: Data from 37 AE-FIP patients (28 men; age 73.9 +/- 7.8 years) were analyzed. With healthy controls as reference, serum M-PN level was significantly higher in patients with AE-FIP (P=0.02) but not in those with stable idiopathic pulmonary fibrosis (P=1.00). M-PN was significantly lower on day 7 than at AE-FIP onset in survivors [14.6 +/- 5.8 vs. 9.3 +/- 2.8 ng/mL (onset to day 7: P<0.001)] but not in non-survivors [14.6 +/- 5.1 vs. 13.2 +/- 5.1 ng/mL (onset to day 7: P=0.07)]. In analysis using a cut-off value for serial change in M-PN (Delta M-PN), 3-month survival was 92.3% in the Delta M-PN decrease group and 36% in the Delta M-PN increase group (P=0.002). In multivariate analysis, 3-month survival tended to be associated with high Delta M-PN (OR: 12.4, 95% CI: 0.82-187.9, P=0.069). Conclusions: Serial change in serum M-PN level may be a prognostic indicator of AE-FIP.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Association of serum high-mobility group box protein 1 level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
    Shimizu, Hiroshige
    Sakamoto, Susumu
    Isshiki, Takuma
    Furuya, Kenta
    Kurosaki, Atsuko
    Homma, Sakae
    PLOS ONE, 2018, 13 (05):
  • [2] Correlation Between Serum Monomeric Periostin And The Prognosis In Patients With Acute Exacerbation Of Fibrosing Interstitial Pneumonia
    Shimizu, H.
    Sakamoto, S.
    Isshiki, T.
    Urabe, N.
    Suzuki, A.
    Gocho, K.
    Sano, G.
    Sugino, K.
    Isobe, K.
    Takai, Y.
    Okamoto, M.
    Hoshino, T.
    Izuhara, K.
    Homma, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [3] Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study
    Abe, Mitsuhiro
    Tsushima, Kenji
    Matsumura, Takuma
    Ishiwata, Tsukasa
    Ichimura, Yasunori
    Ikari, Jun
    Terada, Jiro
    Tada, Yuji
    Sakao, Seiichirou
    Tanabe, Nobuhiro
    Tatsumi, Koichiro
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 5755 - 5762
  • [4] Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis
    Enomoto, Noriyuki
    Naoi, Hyogo
    Aono, Yuya
    Katsumata, Mineo
    Horiike, Yasuoki
    Yasui, Hideki
    Karayama, Masato
    Hozumi, Hironao
    Suzuki, Yuzo
    Furuhashi, Kazuki
    Fujisawa, Tomoyuki
    Inui, Naoki
    Nakamura, Yutaro
    Suda, Takafumi
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2020, 14
  • [5] Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis
    Park, I-Nae
    Kim, Dong Soon
    Shiin, Tae Sun
    Lim, Chae-Man
    Do Lee, Sang
    Koh, Younsuck
    Kim, Woo Sung
    Kim, Won Dong
    Jang, Se Jin
    Colby, Thomas V.
    CHEST, 2007, 132 (01) : 214 - 220
  • [6] Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
    Kondoh, Y
    Taniguchi, H
    Yokoi, T
    Nishiyama, O
    Ohishi, T
    Kato, T
    Suzuki, K
    Suzuki, R
    EUROPEAN RESPIRATORY JOURNAL, 2005, 25 (03) : 528 - 533
  • [7] Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP
    Nagai, S
    Kitaichi, M
    Itoh, H
    Nishimura, K
    Izumi, T
    Colby, TV
    EUROPEAN RESPIRATORY JOURNAL, 1998, 12 (05) : 1010 - 1019
  • [8] Accumulation of periostin in acute exacerbation of familial idiopathic pulmonary fibrosis
    Murata, Keisuke
    Koga, Yasuhiko
    Kasahara, Norimitsu
    Hachisu, Yoshimasa
    Nunomura, Satoshi
    Nakajima, Nozomi
    Yokoo, Hideaki
    Kaira, Kyoichi
    Maeno, Toshitaka
    Dobashi, Kunio
    Izuhara, Kenji
    Hisada, Takeshi
    JOURNAL OF THORACIC DISEASE, 2018, 10 (07) : E587 - E591
  • [9] Cyclosporin A in idiopathic chronic fibrosing interstitial pneumonia without idiopathic pulmonary fibrosis
    Takei, Reoto
    Arita, Machiko
    Tokioka, Fumiaki
    Tachibana, Hiromasa
    Tokumasu, Hironobu
    Ishida, Tadashi
    JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : 6695 - 6701
  • [10] Idiopathic Pulmonary Fibrosis and Nonspecific Interstitial Pneumonia: A Diagnostic Conundrum
    Brooks, A.
    Doan, B.
    Pizzimenti, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199